Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src

ACS Chemical Biology

Volumn 8, Issue 12, 2013, Pages 2734-2743

  Hari, Sanjay B ^a   Perera, B Gayani K ^a   Ranjitkar, Pratistha ^a   Seeliger, Markus A ^b   Maly, Dustin J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; IMATINIB; PHOSPHATE; PROTEIN TYROSINE KINASE; REBASTINIB;

ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BENZAMIDES; BINDING SITES; ENZYME ACTIVATION; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; KINETICS; LIGANDS; MOLECULAR DOCKING SIMULATION; MUTATION; PHOSPHATES; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RECOMBINANT PROTEINS; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890823201     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400663k     Document Type: Article

References (48)

1. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome Science 298, 1912-1934
2. Manning, G., Plowman, G. D., Hunter, T., and Sudarsanam, S. (2002) Evolution of protein kinase signaling from yeast to man Trends. Biochem. Sci. 27, 514-520
3. Kornev, A. P., Haste, N. M., Taylor, S. S., and Eyck, L. F. (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc. Natl. Acad. Sci. U.S.A. 103, 17783-17788
4. Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., and Kuriyan, J. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms Mol. Cell 42, 9-22
5. Kornev, A. P. and Taylor, S. S. (2010) Defining the conserved internal architecture of a protein kinase Biochim. Biophys. Acta 1804, 440-444
6. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289, 1938-1942
7. Dar, A. C., Lopez, M. S., and Shokat, K. M. (2008) Small molecule recognition of c-Src via the Imatinib-binding conformation Chem. Biol. 15, 1015-1022
8. Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., Kuriyan, J., and Maly, D. J. (2009) Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res. 69, 2384-2392
9. De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., and Kim, S. H. (1993) Crystal structure of cyclin-dependent kinase 2 Nature 363, 595-602
10. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64, 6652-6659
11. Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., and Kuriyan, J. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain PLoS Biol. 4, e144
12. Krishnamurty, R., Brigham, J. L., Leonard, S. E., Ranjitkar, P., Larson, E. T., Dale, E. J., Merritt, E. A., and Maly, D. J. (2013) Active site profiling reveals coupling between domains in SRC-family kinases Nat. Chem. Biol. 9, 43-50
13. Wodicka, L. M., Ciceri, P., Davis, M. I., Hunt, J. P., Floyd, M., Salerno, S., Hua, X. H., Ford, J. M., Armstrong, R. C., Zarrinkar, P. P., and Treiber, D. K. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry Chem. Biol. 17, 1241-1249
14. Tanis, K. Q., Veach, D., Duewel, H. S., Bornmann, W. G., and Koleske, A. J. (2003) Two distinct phosphorylation pathways have additive effects on Abl family kinase activation Mol. Cell. Biol. 23, 3884-3896
15. Seeliger, M. A., Nagar, B., Frank, F., Cao, X., Henderson, M. N., and Kuriyan, J. (2007) c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty Structure 15, 299-311
16. Manley, P. W., Cowan-Jacob, S. W., Fendrich, G., Jahnke, W., and Fabbro, D. (2011) Nilotinib, in comparison to both Dasatinib and Imatinib, possesses a greatly prolonged residence time when bound to the BCR-ABL Kinase SH1 domain, in ASH Annual Meeting Abstracts, pp 118-1674, American Society of Hematology, Washington, DC.
17. Zhang, Y. Y., Mei, Z. Q., Wu, J. W., and Wang, Z. X. (2008) Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states J. Biol. Chem. 283, 26591-26601
18. Angell, R. M., Angell, T. D., Bamborough, P., Bamford, M. J., Chung, C. W., Cockerill, S. G., Flack, S. S., Jones, K. L., Laine, D. I., Longstaff, T., Ludbrook, S., Pearson, R., Smith, K. J., Smee, P. A., Somers, D. O., and Walker, A. L. (2008) Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes Bioorg. Med. Chem. Lett. 18, 4433-4437
19. Dumas, J., Hatoum-Mokdad, H., Sibley, R., Riedl, B., Scott, W. J., Monahan, M. K., Lowinger, T. B., Brennan, C., Natero, R., Turner, T., Johnson, J. S., Schoenleber, R., Bhargava, A., Wilhelm, S. M., Housley, T. J., Ranges, G. E., and Shrikhande, A. (2000) 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors Bioorg. Med. Chem. Lett. 10, 2051-2054
20. Cumming, J. G., McKenzie, C. L., Bowden, S. G., Campbell, D., Masters, D. J., Breed, J., and Jewsbury, P. J. (2004) Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase Bioorg. Med. Chem. Lett. 14, 5389-5394
21. Regan, J., Pargellis, C. A., Cirillo, P. F., Gilmore, T., Hickey, E. R., Peet, G. W., Proto, A., Swinamer, A., and Moss, N. (2003) The kinetics of binding to p38MAP kinase by analogues of BIRB 796 Bioorg. Med. Chem. Lett. 13, 3101-3104
22. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9, 268-272
23. Sullivan, J. E., Holdgate, G. A., Campbell, D., Timms, D., Gerhardt, S., Breed, J., Breeze, A. L., Bermingham, A., Pauptit, R. A., Norman, R. A., Embrey, K. J., Read, J., VanScyoc, W. S., and Ward, W. H. (2005) Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase Biochemistry 44, 16475-16490
24. Huang, W. S., Metcalf, C. A., Sundaramoorthi, R., Wang, Y., Zou, D., Thomas, R. M., Zhu, X., Cai, L., Wen, D., Liu, S., Romero, J., Qi, J., Chen, I., Banda, G., Lentini, S. P., Das, S., Xu, Q., Keats, J., Wang, F., Wardwell, S., Ning, Y., Snodgrass, J. T., Broudy, M. I., Russian, K., Zhou, T., Commodore, L., Narasimhan, N. I., Mohemmad, Q. K., Iuliucci, J., Rivera, V. M., Dalgarno, D. C., Sawyer, T. K., Clackson, T., and Shakespeare, W. C. (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J. Med. Chem. 53, 4701-4719
25. Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., Miller, D., Patt, W. C., Smith, B. D., Petillo, P. A., Rutkoski, T. J., Telikepalli, H., Vogeti, L., Yao, T., Chun, L., Clark, R., Evangelista, P., Gavrilescu, L. C., Lazarides, K., Zaleskas, V. M., Stewart, L. J., Van Etten, R. A., and Flynn, D. L. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036 Cancer Cell 19, 556-568
26. DiMauro, E. F., Newcomb, J., Nunes, J. J., Bemis, J. E., Boucher, C., Buchanan, J. L., Buckner, W. H., Cee, V. J., Chai, L., Deak, H. L., Epstein, L. F., Faust, T., Gallant, P., Geuns-Meyer, S. D., Gore, A., Gu, Y., Henkle, B., Hodous, B. L., Hsieh, F., Huang, X., Kim, J. L., Lee, J. H., Martin, M. W., Masse, C. E., McGowan, D. C., Metz, D., Mohn, D., Morgenstern, K. A., Oliveira-dos-Santos, A., Patel, V. F., Powers, D., Rose, P. E., Schneider, S., Tomlinson, S. A., Tudor, Y. Y., Turci, S. M., Welcher, A. A., White, R. D., Zhao, H., Zhu, L., and Zhu, X. (2006) Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity J. Med. Chem. 49, 5671-5686
27. MacAuley, A. and Cooper, J. A. (1989) Structural differences between repressed and derepressed forms of p60c-src Mol. Cell. Biol. 9, 2648-2656
28. Cartwright, C. A., Eckhart, W., Simon, S., and Kaplan, P. L. (1987) Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain Cell 49, 83-91
29. Seeliger, M. A., Young, M., Henderson, M. N., Pellicena, P., King, D. S., Falick, A. M., and Kuriyan, J. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases Protein Sci. 14, 3135-3139
30. Osusky, M., Taylor, S. J., and Shalloway, D. (1995) Autophosphorylation of purified c-Src at its primary negative regulation site J. Biol. Chem. 270, 25729-25732
31. Patschinsky, T., Hunter, T., Esch, F. S., Cooper, J. A., and Sefton, B. M. (1982) Analysis of the sequence of amino acids surrounding sites of tyrosine phosphorylation Proc. Natl. Acad. Sci. U.S.A. 79, 973-977
32. Ranjitkar, P., Brock, A. M., and Maly, D. J. (2010) Affinity reagents that target a specific inactive form of protein kinases Chem. Biol. 17, 195-206
33. Shieh, W.-C., McKenna, J., Sclafani, J. A., Xue, S., Girgis, M., Vivelo, J., Radetich, B., and Prasad, K. (2008) Syntheses of a triad of Flt3 kinase inhibitors: From bench to pilot plant Organic Process Res. Dev. 12, 1146-1155
34. Lin, Y. L., Meng, Y., Jiang, W., and Roux, B. (2013) Explaining why Gleevec is a specific and potent inhibitor of Abl kinase Proc. Natl. Acad. Sci. U.S.A. 110, 1664-1669
35. Lovera, S., Sutto, L., Boubeva, R., Scapozza, L., Dolker, N., and Gervasio, F. L. (2012) The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation J. Am. Chem. Soc. 134, 2496-2499
36. Deininger, M., Buchdunger, E., and Druker, B. J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105, 2640-2653
37. Zhou, T., Commodore, L., Huang, W. S., Wang, Y., Sawyer, T. K., Shakespeare, W. C., Clackson, T., Zhu, X., and Dalgarno, D. C. (2010) Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template Chem. Biol. Drug Des. 75, 18-28
38. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 112, 859-871
39. Underbakke, E. S., Zhu, Y., and Kiessling, L. L. (2008) Isotope-coded affinity tags with tunable reactivities for protein footprinting Angew. Chem., Int. Ed. 47, 9677-9680
40. Wang, L., Perera, B. G., Hari, S. B., Bhhatarai, B., Backes, B. J., Seeliger, M. A., Schurer, S. C., Oakes, S. A., Papa, F. R., and Maly, D. J. (2012) Divergent allosteric control of the IRE1alpha endoribonuclease using kinase inhibitors Nat. Chem. Biol. 8, 982-989
41. Hari, S. B., Merritt, E. A., and Maly, D. J. (2013) Sequence determinants of a specific inactive protein kinase conformation Chem. Biol. 20, 806-815
42. Kwarcinski, F. E., Fox, C. C., Steffey, M. E., and Soellner, M. B. (2012) Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine ACS Chem. Biol. 7, 1910-1917
43. Zhou, T., Commodore, L., Huang, W. S., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., Dalgarno, D. C., and Zhu, X. (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance Chem. Biol. Drug Des. 77, 1-11
44. Piserchio, A., Cowburn, D., and Ghose, R. (2012) Expression and purification of Src-family kinases for solution NMR studies Methods Mol. Biol. 831, 111-131
45. Hari, S. B., Ranjitkar, P., and Maly, D. J. (2012) Determination of the kinetics and thermodynamics of ligand binding to a specific inactive conformation in protein kinases Methods Mol. Biol. 928, 153-159
46. Flynn, D. L., Petillo, P. A., and Kaufman, M. D. Kinase inhibitors useful for the treatment of myeloproliferative diseases and other proliferative diseases, U.S. Patent 7790756, 2010, Deciphera Pharmaceuticals, LLC.
47. Hodous, B. L., Geuns-Meyer, S. D., Hughes, P. E., Albrecht, B. K., Bellon, S., Bready, J., Caenepeel, S., Cee, V. J., Chaffee, S. C., Coxon, A., Emery, M., Fretland, J., Gallant, P., Gu, Y., Hoffman, D., Johnson, R. E., Kendall, R., Kim, J. L., Long, A. M., Morrison, M., Olivieri, P. R., Patel, V. F., Polverino, A., Rose, P., Tempest, P., Wang, L., Whittington, D. A., and Zhao, H. (2007) Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3, 5-triazine Tie-2 kinase inhibitor J. Med. Chem. 50, 611-626
48. Ranjitkar, P., Perera, B. G., Swaney, D. L., Hari, S. B., Larson, E. T., Krishnamurty, R., Merritt, E. A., Villen, J., and Maly, D. J. (2012) Affinity-based probes based on type II kinase inhibitors J. Am. Chem. Soc. 134, 19017-19025